Presentations & Publications

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- Vutisiran HCRU and discontinuation

PRESENTATION · Nov 2025 · PDF

Acoramidis-AHA 2025- Variant ACM and First CVH

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- p.V142I (V122I) ACM analysis

PRESENTATION · Sep 2025 · PDF

Acoramidis-HFSA-2025-NT-proBNP-in-ATTRv-CM

PRESENTATION · Sep 2025 · PDF

Acoramidis-HFSA-2025-OLE-ACM-and-CVH-by-Genotype

PRESENTATION · Aug 2025 · PDF

BBIO - Acoramidis TTR- ESC 2025 - Improvement in NT-proBNP

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Improvement in Serum TTR Levels in Wild-type or Variant Transthyretin Amyloid Cardiomyopathy

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Functional Capacity and Quality of Life in Variant ATTR-CM from ATTRibute-CM

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - All-cause Mortality, Cardiovascular Hospitalization and NT-proBNP in Variant ATTR-CM from ATTRibute-CM

PRESENTATION · Apr 2025 · PDF

Acoramidis TTR - ACC 2025 - Improvements in Serum TTR Levels in Variant Population

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ISA 2024 - Rationale & design of ACT-EARLY

PRESENTATION · Dec 2023 · PDF

Acoramidis - ESC 2023 - Acoramidis Produces Near-Complete TTR Stabilization in Variant ATTR Patients that is Greater than that Achieved with Tafamidis